文献速递心脑血管急症消化、代谢与肾脏急症

他汀类药物用于50至75岁成人心血管事件一级预防的获益时间评估:一项Meta分析

Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis.
PubMed 文献 · JAMA Intern Med · 2021-01-01
一句话结论50-75岁无心血管病成人他汀一级预防约需2.5年(95%CI 1.7-3.4)才避免1例MACE/100人治疗,无死亡率获益证据;预期寿命不足2.5年者可能无法获益。

结果显示,每治疗100人需2.5年(95%CI 1.7-3.4)避免1例首次MACE;ARR=0.005(每200人避免1例)的获益时间为1.3年(95%CI 1.0-1.7),ARR=0.002(每500人避免1例)为0.8年(95%CI 0.5-1.0)。仅1/8研究显示他汀降低全因死亡率。结论提示,预期寿命至少2.5年的50-75岁无心血管病成人可考虑他汀一级预防,但无死亡率获益证据。

要点

  • 50-75岁无心血管病成人他汀一级预防:每100人治疗2.5年(95%CI 1.7-3.4)避免1例首次MACE。
  • 每200人治疗避免1例MACE(ARR=0.005)的获益时间为1.3年(95%CI 1.0-1.7)。
  • 每500人治疗避免1例MACE(ARR=0.002)的获益时间为0.8年(95%CI 0.5-1.0)。
  • 8项RCT中仅1项显示他汀降低全因死亡率,无死亡率获益证据。
  • 预期寿命不足2.5年的50-75岁成人,他汀一级预防可能无法在生前获得MACE获益。

适用人群与场景

  • 排除标准:原文未提及。
  • 适用场景:原文未提及急诊/ICU/院前具体场景;研究针对门诊一级预防人群。

诊断标准与关键阈值

  • 主要结局为首次MACE,各试验定义宽泛相似,均包括心肌梗死和心血管死亡。
  • 获益时间(TTB)以绝对风险降低(ARR)阈值0.002、0.005、0.010定义:ARR=0.002对应每500人治疗避免1例MACE,ARR=0.005对应每200人避免1例,ARR=0.010对应每100人避免1例。
  • 原文未给出他汀启动/停止的具体阈值或评分界值。

处置流程与药物剂量

  • 原文未提及具体他汀药名、剂量、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 干预与对照:他汀 vs 对照(一级预防)。
  • 主要终点:每100人治疗避免1例首次MACE需2.5年(95%CI 1.7-3.4);ARR=0.005(每200人避免1例)的TTB为1.3年(95%CI 1.0-1.7);ARR=0.002(每500人避免1例)的TTB为0.8年(95%CI 0.5-1.0)。
  • 关键次要终点:仅1/8研究显示他汀降低全因死亡率;无死亡率获益证据。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:随机临床试验的生存Meta分析(8项RCT)。
  • 证据等级或推荐强度:原文未给出。
  • 局限:仅1/8研究显示全因死亡率下降;各试验MACE定义宽泛相似但未完全统一;平均随访2-6年;原文未提及其他局限。

对床旁实践的改变

  • 对50-75岁无已知心血管病成人启动他汀一级预防前,应评估预期寿命:至少2.5年才可能在生前获得1例/100人治疗的MACE获益。
  • 预期寿命不足2.5年者,他汀一级预防的MACE获益可能无法实现;不应以降低死亡率为目的启动他汀一级预防(无死亡率获益证据)。
  • 原文未提及急诊/ICU场景下的具体做法改变;不适用于已知心血管病的二级预防人群。

指南或共识出处

  • 原文未提及具体指南或共识名称;文中提及数据来源为Cochrane Database of Systematic Reviews和US Preventive Services Task Force的系统评价。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Guidelines recommend targeting preventive interventions toward older adults whose life expectancy is greater than the intervention's time to benefit (TTB). The TTB for statin therapy is unknown.

OBJECTIVE: To conduct a survival meta-analysis of randomized clinical trials of statins to determine the TTB for prevention of a first major adverse cardiovascular event (MACE) in adults aged 50 to 75 years.

DATA SOURCES: Studies were identified from previously published systematic reviews (Cochrane Database of Systematic Reviews and US Preventive Services Task Force) and a search of MEDLINE and Google Scholar for subsequently published studies until February 1, 2020.

STUDY SELECTION: Randomized clinical trials of statins for primary prevention focusing on older adults (mean age >55 years).

DATA EXTRACTION AND SYNTHESIS: Two authors independently abstracted survival data for the control and intervention groups. Weibull survival curves were fit, and a random-effects model was used to estimate pooled absolute risk reductions (ARRs) between control and intervention groups each year. Markov chain Monte Carlo methods were applied to determine time to ARR thresholds.

MAIN OUTCOMES AND MEASURES: The primary outcome was time to ARR thresholds (0.002, 0.005, and 0.010) for a first MACE, as defined by each trial. There were broad similarities in the definition of MACE across trials, with all trials including myocardial infarction and cardiovascular mortality.

RESULTS: Eight trials randomizing 65 383 adults (66.3% men) were identified. The mean age ranged from 55 to 69 years old and the mean length of follow-up ranged from 2 to 6 years. Only 1 of 8 studies showed that statins decreased all-cause mortality. The meta-analysis results suggested that 2.5 (95% CI, 1.7-3.4) years were needed to avoid 1 MACE for 100 patients treated with a statin. To prevent 1 MACE for 200 patients treated (ARR = 0.005), the TTB was 1.3 (95% CI, 1.0-1.7) years, whereas the TTB to avoid 1 MACE for 500 patients treated (ARR = 0.002) was 0.8 (95% CI, 0.5-1.0) years.

CONCLUSIONS AND RELEVANCE: These findings suggest that treating 100 adults (aged 50-75 years) without known cardiovascular disease with a statin for 2.5 years prevented 1 MACE in 1 adult. Statins may help to prevent a first MACE in adults aged 50 to 75 years old if they have a life expectancy of at least 2.5 years. There is no evidence of a mortality benefit.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Yourman LC, Cenzer IS, Boscardin WJ, et al. Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. JAMA Intern Med. 2021. PMID: 33196766. doi:10.1001/jamainternmed.2020.6084

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。